References
ADRAC (Australian Adverse Drug Reactions Advisory Committee). Mianserin: a possible cause of neutropenia and agranulocytosis. Medical Journal of Australia 2: 673, 1980
ADRAC. Prazosin hydrochloride and urinary incontinence. Australian Adverse Drug Reactions Bulletin, September 1983
ADRAC. Moduretic hyponatraemia. Australian Adverse Drug Reactions Bulletin, November 1984
Editorial. Improving reports of adverse drug reactions. British Medical Journal 289: 898, 1984
Edwards IR. Adverse drug reaction monitoring: the practicalities. Medical Toxicology 2: 405–410, 1987
Farrell G, et al. Halothane hepatitis: detection of a constitutional susceptibility factor. New England Journal of Medicine 313: 1310, 1985
Goulston SJM. Immediate reactions to measles vaccine: comment by ADEC — and a request for information. Medical Journal of Australia 2: 313, 1981
Henry DA. The Industries Assistance Commission Draft Report on Pharmaceutical Products. The likely impact on drug regulation in Australia. Medical Journal of Australia 144: 256, 1986a
Henry DA. NSAIDs: do they really cause upper gastrointestinal haemorrhage? (editorial). Current Therapeutics 27(5): 13–17, 1986b
Henry DA, et al. Glucomannan and risk of oesophageal obstruction. British Medical Journal 292: 591, 1985
Inman WHW. Let’s get our act together. In Dukes MNG (Ed.) Side Effects of Drugs Annual 9, pp. xv–xxiii, Elsevier, Amsterdam, 1985
Inman WHW. Requirements for risk-benefit assessment of drugs before withdrawal. British Institute of Regulatory Affairs Journal 5(2): 11–15, 1986
Inman WHW, Rawson NSB. Peptic ulcer and piroxicam. British Medical Journal 290: 932–933, 1985
Lasagna L. Discussion of paper by Dukes MNG. The epidemiology of adverse reactions. In Bostrom & Ljungstedt (Eds). Detection and prevention of adverse drug reactions, pp. 15–30, Almqvist & Wiskell International, Stockholm, 1984
Maclay WP, Crowder D, Spiro S, Turner P. Postmarketing surveillance: practical experience with ketotifen. British Medical Journal 288: 911–914, 1984
McEwen J. Phenylpropanolamine-associated hypertension after the use of ‘over-the-counter’ appetite-suppressant products. Medical Journal of Australia 2: 71, 1983a
McEwen J. Early-onset reaction after measles vaccination: further Australian reports. Medical Journal of Australia 2: 503, 1983b
McEwen J, Meyboom RHB. Testicular pain caused by mazindol. British Medical Journal 287: 1763, 1983
McEwen J, Strickland WJ. Mebhydrolin napadisylate: a possible cause of reversible agranulocytosis and neutropenia. Medical Journal of Australia 2: 523, 1983
Mashford ML. Australia. In Inman WHW (Ed.) Monitoring for Drug Safety, pp. 49–57, MTP Press Limited, Lancaster, 1986
Morse ML. The Compass data base. Drug Information Journal 19: 249–252, 1985
Olsson S, et al. Photosensitivity during treatment with azapropazone. British Medical Journal 291: 939, 1985
Rossi AC, Knapp DE, Anello C, O’Neill RT, Graham CF, Mendelis PS, et al. Discovery of adverse drug reactions: a comparison of selected Phase IV studies with spontaneous reporting methods. Journal of the American Medical Association 249: 2226–2228, 1983
Sheffield LJ, Batagol R. The creation of therapeutic orphans — or, what have we learnt from the Debendox fiasco? Medical Journal of Australia 143: 143, 1985
Stricker BHCh, et al. Acute hypersensitivity reactions to paracetamol. British Medical Journal 291: 938, 1985
Venning GR. Identification of adverse reactions to new drugs. Part III: Alerting processes and early warning systems. British Medical Journal 286: 458–460, 1983a
Venning GR. Identification of adverse reactions to new drugs. Part IV: Verification of suspected adverse reactions. British Medical Journal 286: 544–547, 1983b
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McEwen, J. Improving Adverse Drug Reaction Monitoring. Med Toxicol Adverse Drug Exp 2, 398–404 (1987). https://doi.org/10.1007/BF03259874
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03259874